Last reviewed · How we verify
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.
Details
| Lead sponsor | Children's Mercy Hospital Kansas City |
|---|---|
| Phase | PHASE4 |
| Status | RECRUITING |
| Enrolment | 60 |
| Start date | Thu Sep 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Sep 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Heart Transplant Infection Prevention
Interventions
- Commercial measles, mumps, and rubella (MMR) vaccine
Countries
United States